君实生物:注射用JS212药物临床试验获批准

人民财讯
20 Mar

  人民财讯3月20日电,君实生物(688180)3月20日晚间公告,近日,公司收到国家药监局核准签发的《药物临床试验批准通知书》,注射用JS212(项目代号“JS212”)的临床试验申请获得批准,同意该药品单药在晚期实体瘤患者中开展临床试验。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10